Genetic factors that influence inflammation and energy production/expenditure in cells may affect patient outcomes following treatment with external beam radiation therapy (EBRT). Sestrins, stress-inducible genes with antioxidant properties, have recently been implicated in several behaviors including fatigue. This proof-of-concept study explored whether the sestrin family of genes (SESN1, SESN2, and SESN3) were differentially expressed from baseline to the midpoint of EBRT in a sample of 26 Puerto Rican men with nonmetastatic prostate cancer. We also examined whether changes in expression of these genes were associated with changes in fatigue scores during EBRT. Method: Participants completed the 13-item Functional Assessment of Cancer Therapy-Fatigue subscale, Spanish version. Whole blood samples were collected at baseline and at the midpoint of EBRT. Gene expression data were analyzed using the limma package in the R (version R 2.14.0.) statistical software. Linear models and empirical Bayes moderation, adjusted for radiation fraction (total number of days of prescribed radiation treatment), were used to examine potential associations between changes in gene expression and change in fatigue scores. Results: Expression of SESN3 (adjusted p < .01, log fold change À0.649) was significantly downregulated during EBRT, whereas the expressions of SESN1 and SESN2 remained unchanged. After adjustment for radiation fraction, change in SESN3 expression was associated with change in fatigue during EBRT (false discovery rate <.01). Conclusions: Downregulation of SESN3, a novel pharmacoactive stress response gene, was associated with fatigue intensification during EBRT. SESN3 may serve as an interventional target and a biomarker for the cellular and molecular events associated with EBRT-related fatigue.
Fatigue is a distressing and commonly reported symptom for patients undergoing radiation therapy (RT) for cancer (Langston, Armes, Levy, Tidey, & Ream, 2013) . It has direct and indirect health and economic consequences from unemployment, increased hospitalizations, noncompliance with treatment, need for dose adjustment, interruption of treatments, or even decreased survival (Aguado Loi et al., 2013; Cleeland, 2007; Franklin & Packel, 2006; Hanna et al., 2015) . However, only a subgroup of patients develop clinically relevant fatigue related to RT (Fransson, 2010; Hsiao, Wang, Kaushal, & Saligan, 2012; Stone, Richards, A'Hern, & Hardy, 2001) , which may be attributable to a unique clinical phenotype and distinct genomic profile that influence treatment response (Feng et al., 2015; Hickok et al., 2005; Ryan et al., 2007; Saligan & Kim, 2012) . Recent evidence suggests that oxidative stress, genomic instability, and differential expression of sestrin genes induced by RT may play an important role in this individual variability regarding the fatigue experience (Broderick et al., 2006; Filler et al., 2014) . Lee, Budanov, and Karin (2013) reported that sestrins are stress-responsive proteins, activated by insults such as genotoxic stress from irradiation and chemotherapy/genotoxic drug treatments. Inactivation of sestrins (downregulation of SESN3) has been associated with oxidative damage and mitochondrial dysfunction (Kopnin, Agapova, Kopnin, & Chumakov, 2007;  Lee, Budanov, & Karin, 2013) . Sestrins can also protect cells from insults through their antioxidant biochemical function, directing reactive oxygen species (ROS) scavenging and attenuating mammalian target of rapamycin (mTORC1)-derived ROS (Parmigiani & Budanov, 2016) . Thus, lifestyle interventions (e.g., exercise, dietary modifications, or antioxidant therapies) that target activation or induction of sestrin genes hold potential as therapeutic options for decreasing the mitochondrial dysfunction of oxidative stress induced by excessive generation of ROS. For example, in a recent study, Lenhare et al. (2017) demonstrated that physical exercise increased levels of the SESN2 protein in skeletal muscles and improved muscle function in older mice.
Sestrin genes have also been associated with symptoms (e.g., fatigue, pain). In one study, the expression of SESN1 was the most discriminating genetic marker for identifying subjects with chronic fatigue versus those without fatigue, though the authors did not mention the direction of change in gene expression (Broderick et al., 2006) . In another study, SESN2-knockout mice displayed increased late-phase, ROS-associated neuropathic pain behavior, suggesting that SESN2 controls ROS-dependent neuropathic pain processing (KallenbornGerhardt et al., 2013) . As an initial effort to determine the role of sestrins in the symptom experience, we conducted this proof-of-concept study to explore whether (1) sestrin genes (SESN1, SESN2, and SESN3) were differentially expressed during RT and (2) changes in the expressions of these genes were associated with changes in fatigue scores reported by patients.
Method and Material

Study Participants
Recruitment and data collection took place at an ambulatory RT facility located in San Juan, Puerto Rico, from July to September 2014. The inclusion criteria were Puerto Rican males over 40 years of age with a clinical diagnosis of nonmetastatic prostate cancer (PC), who were scheduled for external beam RT (EBRT). Eligible participants also needed to be able to read and write Spanish at the sixth-grade level and to provide written informed consent. Exclusion criteria included the following progressive or unstable disease of a bodily system causing clinically significant fatigue; chronic inflammatory disease, systemic infections; documented history of major psychiatric disorder; uncorrected hypothyroidism or anemia; second malignancies; and chemotherapy concurrent with their EBRT. We collected demographics (age, years of education) and clinical characteristics of participants by chart review. The Human Subjects Committees of both the Academic Medical Center and University of Puerto Rico Medical Science Campus approved the study prior to data collection.
To test our hypothesis, we collected study outcomes (fatigue score and blood draw for genotyping) at two time points: baseline (before EBRT) and at midpoint of EBRT (around Day 18-21 from EBRT initiation). In prior studies, researchers have observed fatigue intensification at the midpoint of EBRT (Hsiao et al., 2012; Saligan et al., 2013 (Baro et al., 2011; Cella et al., 1998) .
A decrease of more than 3 points in the FACT-F score between time points represents a clinically relevant change (Cella, Eton, Lai, Peterman, & Merkel, 2002) . To optimize the fatigue phenotypic characterization of the study participants, we grouped participants for analysis based on a !3-point change in FACT-F score from pre-to midpoint of EBRT such that worsened fatigue (WF) patients were those with a !3-point decrease in FACT-F score, nonfatigued (NF) patients were those with a 2-point change in fatigue score, and improvement in fatigue (IF) patients were those with a !3-point increase in fatigue score.
Gene Expression Microarray
We collected a total of 2.5 ml of peripheral blood using RNA PAXGene tubes (QIAGEN, Frederick, MD) for each of the two study time points. De-identified blood samples were stored in a securely locked À80 C freezer until shipment to the National Institute of Nursing Research (NINR) laboratory. RNA extraction, purification, complementary DNA and complementary RNA synthesis, amplification, hybridization, scanning, and data analyses were conducted in the NINR lab following standard protocols described in a prior publication (Hsiao et al., 2012) . To assess gene expression levels for genes across the genome, 52 Affymetrix microarray chips (HG U133 Plus 2.0, Santa Clara, CA) were used. The Affymetrix GeneChip Command Console (3.0 V) was used to scan the images for data acquisition.
Statistical Analysis
We computed descriptive statistics, including mean, median, and standard deviation (SD), for the demographic and disease characteristics of the sample. In addition, we computed the mean and SD for FACT-F scores at each time point for the sample as a whole and by fatigue group. To evaluate the relationships between baseline FACT-F, change in fatigue scores, radiation fraction, and age, we assessed Pearson correlations. We used the limma package with R for normalization of the Affymetrix intensity data. We analyzed the association between changes in gene expression and fatigue scores using linear models and empirical Bayes moderations, adjusting for radiation fraction. To adjust for the testing of thousands of genes, we used the Benjamini-Hochberg approach to estimate the false discovery rate (FDR).
Results
We approached 31 men for possible participation in the study; 28 agreed to participate, but only 26 were eligible and were consented (2 were ineligible due to chronic renal failure). The mean age of study participants was 67.01 years (SD ¼ 7.56), the large majority were married or partnered (96%), well educated (85%), and retired (69%). Table 1 describes the clinical characteristics of the participants. Almost half of the participants had low-risk disease with a clinical stage of T2 (46%) and a Gleason score of 6-9. More than half of the men (58%) had received neoadjuvant hormonal therapy (androgen deprivation therapy) 8 weeks prior to the initiation of EBRT, and 23% had undergone radical prostatectomy more than a year before receiving EBRT. Regarding RT fractions for the total sample, 11 men (42%) received a total of 43 fractions with 77.4 gray (Gy), 6 (23%) had 42 fractions with 75.6 Gy, another 6 (23%) received 38 fractions with 68.4 Gy, 2 (8%) received 39 fractions with 70.2 Gy, and 1 (4%) had a total of 41 fractions with 73.8 Gy using the intensity-modulated RT technique. Baseline hemoglobin, albumin, and thyroid-stimulating hormone were within reference ranges.
Most participants were in the NF group (n ¼ 17), while four were in the IF (n ¼ 4) and five in the WF groups. Figure 1 depicts the change in individual fatigue scores by group. The mean fatigue score did not change significantly from baseline (42.38 + 9.34) to the midpoint (42.11 + 8.93), t (24) SESN1, SESN2, and SESN3 were differentially expressed between baseline and the midpoint of EBRT for the sample as a whole. After FDR correction (FDR .01), only SESN3 (probe 235684_s_at) was significantly downregulated during EBRT, while the expressions of SESN1 and SESN2 remained unaltered (Table 2 ). Differential expressions of two probes of SESN3 (235684_s_at and 235683_at; again after FDR correction [FDR .01]) were significantly associated with changes in fatigue (DFACT-F score) in all study participants, after adjusting for RT fraction (Table 3) . To determine whether specific SESN3 probes could identify patients in different fatigue categories, we conducted a visual inspection of the trajectory of the different SESN3 probes and discovered that SESN3 (probe 242906_at) was downregulated in three of the five participants in the WF group (60% accuracy), while it was upregulated in most participants in the IF and NF groups (except one IF subject; Figure 2D ). SESN3 (probe 225123_at) was also upregulated in four of the five WF participants (80% accuracy) but was mostly downregulated in the IF and NF participants ( Figure 2C ). The other two SESN3 probes (probes 235684_s_at, 235683_at) were less accurate in predicting fatigue grouping, suggesting that further investigations are necessary to validate the sensitivity of SESN3 as a potential biomarker for fatigue intensification during EBRT.
Discussion
This proof-of-concept study is the first to present evidence that sestrins may have an important role in fatigue intensification during EBRT. This finding has at least two implications: (1) deficient adaptive response to insults from cancer therapies may have a role in the fatigue experience and (2) sestrins may be a feasible interventional target for reducing the effects of oxidative stress through antioxidant supplementation or exercise.
This preliminary analysis suggests that SESN3 is expressed in blood and that its differential expression is influenced by responses to RT-related injury. Investigators have also observed that SESN3 (messenger RNA) is overexpressed in other tissues (e.g., skeletal muscle) in patients with type 2 diabetes, where it has been linked with clinical markers of glucose homeostasis (e.g., fasting plasma glucose, 2-hr postprandial plasma glucose, HbA1c; Nascimento, Osler, & Zierath, 2013) . All these prior observations about associations with SESN3 expression seem to point to mechanisms that researchers have proposed to explain the biologic underpinnings of cancer-related fatigue: metabolic pathways, oxidative stress, and the musculoskeletal system (Filler et al., 2014; Ryan et al., 2007; Saligan & Kim, 2012) . Findings of the current study regarding the association of SESN3 and fatigue are inconclusive but promising. Figure 2 suggests that downregulation of SESN3, specifically probe 242906_at, influences fatigue intensification during EBRT. However, two participants in the WF group had upregulated expression of SESN3 (probe 242906_at) during EBRT. A closer investigation, however, revealed that the changes in FACT-F scores (median ¼ 5) of these two WF participants were smaller than the changes in FACT-F scores (median ¼ 15) we observed in the three WF participants with downregulated SESN3 (probe 242906_at), suggesting that downregulation of SESN3 (probe 242906_at) may be a good marker for a more pronounced worsening of fatigue during EBRT.
Sestrins are stress-responsive genes that balance adenosine monophosphate-dependent-activated protein kinase (AMPK) and mTOR signaling (Nascimento et al., 2013) . Nogueira et al.'s (2008) study findings suggest that in vitro expression of SESN3 in mouse embryonic fibroblast reduces mTORC1 activity, providing evidence of the relationship of sestrins and the mTOR-signaling pathway. There is also evidence from rodent studies that altered AMPK-and mTOR-signaling pathways are linked to the development of fatigue (Song et al., 2015) . Therefore, it is plausible that sestrins may play a role in fatigue intensification during RT through these mechanisms. Further studies are needed to investigate the role of AMPKand mTOR-signaling pathways in RT-related fatigue. Our model proposes that external inactivation of SESN3 leads to the downstream molecular and cellular events that influence fatigue development during RT (Figure 3) . One potential mechanism of the association between SESN3 and RT-related fatigue, as suggested by the findings described above, is ionizing radiation-induced downregulation of SESN3 expression (inactivation of sestrin 3) causing deregulation of the AMPKand mTOR-signaling pathways. Deregulation of these pathways can lead to mitophagy (dysfunctional mitochondria), in which respiratory function declines and oxidative stress increases. An increase in oxidative stress leads to an imbalance in the metabolism of ROS and reactive nitrogen species (RNS) and impairment of the cell's ability to detoxify ROS, RNS, and other reactive metabolic intermediates (Lee et al., 2013) . Hence, the oxidative stress state can culminate in the metabolic shift from mitochondrial respiration to the glycolysis pathway for supply of adenosine triphosphate (ATP). ATP is a vital energy source for cells; thus, a reduction in ATP production can lead to an individual feeling fatigued (Hsiao et al., 2012) .
Limitations
We had a relatively small sample size in the present study. A larger sample with longer follow-up is needed for validation and closer observations of the associations of fatigue with the expression of sestrin genes related to RT. It is also important to collect additional information on factors that can influence the association of fatigue and gene expression related to RT, such as changes in levels of hemoglobin, weight, nutritional status, physical activity, sleep, and depressive symptoms. Finally, we recruited our sample from a single site; therefore, findings may not truly reflect the broader population of men with PC in Puerto Rico.
Clinical Implications
In the present proof-of-concept study, we found that the SESN3 gene, which is implicated in oxidative stress, was downregulated at the midpoint of EBRT and was associated with fatigue intensification during RT. Confirmatory testing of the altered expression of this gene is required as well as the evaluation of SESN3 as a potential biomarker that can discriminate fatigued from NF patients. Fatigue is a multidimensional symptom that can be influenced by several factors such as age and RT dose. In the present study, however, fatigue symptoms were not influenced by either age or RT dose, which is consistent with prior reports involving this clinical population (Hickok et al., 2005; Truong et al., 2006) . This finding suggests that advances in RT have allowed for the irradiating of tumors using higher doses while minimizing the effects of RT on adjacent tissues and organs. Nevertheless, because of individual variability in treatment response, routine assessment and management of symptoms during any cancer therapy are necessary.
The sestrins' role in reducing oxidative stress makes them a feasible interventional target. Recent studies have suggested that lifestyle interventions including regular exercise, dietary modifications, and antioxidant therapies (i.e., vitamin E and C, herbal medicines) reduce the overproduction of ROS and oxidative damage, promoting mitochondrial biogenesis Bhatti, Kumar, Vijayan, Bhatti, & Reddy, 2017) . For example, Anderson, Milne, Sandler, and Nichols (2016) found significant inverse associations between physical activity and intake of fruits/vegetables and antioxidant nutrients (i.e., vitamin C, vitamin E) and oxidative stress as measured by urine concentrations of F2-isoprostane and/or its metabolite among 912 premenopausal women. Additionally, given the role of sestrins in detoxifying ROS, it is plausible that lifestyle interventions targeting activation or upregulation of sestrin genes could provide insight into the prevention or amelioration of RT-related fatigue. For example, authors have proposed that the antioxidant and AMPK-modulating functions of sestrins are associated with the beneficial effects of physical exercise (Liu, Niu, Yuan, Huang, & Fu, 2015; Sanchis-Gomar, 2013) . Liu, Niu, Yuan, Huang, and Fu (2015) found a significant increase in the protein expression of both SESN2 and SESN3 in response to a single bout of treadmill exercise in C57BL/6 wild-type (WT) mice fed both normal-and high-fat diets compared to AMPK a2(1/1) mice, confirming the relationship of sestrins and the AMPK-signaling pathway. In addition, they found that long-term exercise training resulted in an increased level of skeletal muscle autophagy (intracellular recycling system) and increased expression of SESN2 and SESN3 in WT mice (i.e., positive for AMPK a2) fed both normal-and high-fat diets. Mounting evidence affirms that exercise reduces cancer-related fatigue (Mustian et al., 2017) .
Furthermore, complementary treatments including herbal medicines (e.g., Paecilomyces hepiali, a fungus) and Cordyceps militaris (mushrooms) significantly delayed fatigue in a mouse model in previous studies (Song et al., 2015; Wang et al., 2016) . In fact, Song et al. (2015) showed that C. militaris administration increased ATP levels and antioxidative enzyme activity and reduced the levels of lactic acid, lactic dehydrogenase, malondialdehyde, and ROS in mice. Song et al. (2015) concluded that the mechanism underlying the association of treatment with C. militaris with fatigue recovery is mainly through activation of 5 0 -AMPK and protein kinase B (AKT)/ mammalian target of rapamycin (mTOR) pathways and regulation of serum hormone levels. To our knowledge, researchers have not yet explored the antioxidant properties of sestrins associated with diet supplementation.
Future studies should explore the roles of exercise and antioxidant supplementation in regulating the expression of sestrin markers and whether these sestrin markers can reduce fatigue during cancer therapy. Our findings in the present study advance our understanding of the cellular and molecular mechanisms underlying fatigue intensification during cancer therapy.
Conclusion
Researchers have previously recognized sestrins for their role in detoxifying ROS through regeneration of peroxiredoxins (Budanov, Sablina, Feinstein, Koonin, & Chumakov, 2004; Kallenborn-Gerhardt et al., 2013; Nascimento et al., 2013) . In the present study, we found that SESN3 is downregulated at the midpoint of EBRT and that this downregulation is associated with fatigue intensification during EBRT. Further validation is warranted to confirm this relationship and explore how this downregulation influences the role of mitochondrial dysfunction in RT-related fatigue (Saligan & Kim, 2012) . Based on these findings, we suggest that sestrins may represent a novel biomarker, therapeutic target, and promising molecular mechanism by which the antioxidant defense system ameliorates RT-related fatigue. More research is thus warranted to elucidate the novel role of sestrins in RT-related fatigue.
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